Fi­bro­Gen eyes re­bound path with Ph1 ADC da­ta for prostate can­cer drug

Af­ter a se­ries of clin­i­cal dis­ap­point­ments, Fi­bro­Gen could be on the come­back trail with promis­ing ear­ly da­ta from a CD46-tar­get­ing an­ti­body-drug con­ju­gate de­vel­oped by part­ner For­tis Ther­a­peu­tics.

The ADC can­di­date, FG-3246, is the sub­ject of a four-year agree­ment made in May 2023 in which Fi­bro­Gen has the op­tion to buy For­tis for $80 mil­lion up­front with the biotech al­so el­i­gi­ble for up to $200 mil­lion in ap­proval-linked mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER